SCHEMBL675705

SCHEMBL675705

[CH2]c1ccc(-c2ccncn2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.51
MAPT P10636 1/20 0.41
MAPK14 Q16539 3/20 0.39
MAPK10 P53779 2/20 0.39
MAPK9 P45984 4/20 0.38
MAPK11 Q15759 2/20 0.38
HSP90AA1 P07900 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
HDAC4 P56524 1/20 0.38
MAP4K4 O95819 2/20 0.37
EGFR P00533 2/20 0.37
FRK P42685 2/20 0.37
CSNK1A1 P48729 2/20 0.37
MAPK13 O15264 1/20 0.37
RAF1 P04049 1/20 0.37
MAPK12 P53778 1/20 0.37
GSK3B P49841 4/20 0.36
PRKACA P17612 2/20 0.36
CLK4 Q9HAZ1 2/20 0.36
DCLK1 O15075 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9903935 0.89 CYP2D6 (0.60) CYP2D6MAPTMAPK14MAPK10MAPK9
SCHEMBL6852363 0.82 CYP2D6 (0.51) CYP2D6MAPTMAPK14MAPK10MAPK9
SCHEMBL8499115 0.81 CYP2D6 (0.53) CYP2D6MAPTMAPK14MAPK10MAPK9
SCHEMBL15651713 0.78 CYP2D6 (0.51) CYP2D6MAPTMAPK14MAPK10MAPK9
SCHEMBL3157652 0.78 NOTUM (0.52) CYP2D6MAPTMAPK14MAPK9MAPK11
SCHEMBL1061567 0.78 CYP2D6 (0.51) CYP2D6MAPTMAPK14MAPK10MAPK9
SCHEMBL2562967 0.78 CYP2D6 (0.56) CYP2D6MAPTMAPK14MAPK10MAPK9
SCHEMBL17690417 0.78 CYP2D6 (0.51) CYP2D6MAPTMAPK14MAPK10MAPK9
SCHEMBL8566727 0.78 CYP2D6 (0.51) CYP2D6MAPTMAPK14MAPK10MAPK9
SCHEMBL31360692 0.78 NOTUM (0.52) CYP2D6MAPTMAPK14MAPK9MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487527-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I INTRA-CELLULAR THERAPIES, INC. (US) 2016-11-08 US disclosed
US-20150119370-A1 Organic Compounds LI PENG (US) 2015-04-30 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
EP-2367430-B1 ORGANIC COMPOUNDS INTRA CELLULAR THERAPIES INC (US) 2014-08-13 EP disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed
CN-102227167-A Organic compounds INTRA CELLULAR THERAPIES INC 2011-10-26 CN disclosed
EP-2367430-A1 ORGANIC COMPOUNDS Intra-Cellular Therapies, Inc. (US) 2011-09-28 EP disclosed
WO-2010065152-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. (US) 2010-06-10 WO disclosed
CN-1310934-C Erythromycin 6-O-carbamoylketolide derivatives useful as antibacterial agents ORTHO MCNEIL PHARM INC (US) 2007-04-18 CN disclosed
CN-1585775-A 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials ORTHO MCNEIL PHARM INC (US) 2005-02-23 CN disclosed
CN-1543472-A 6-o-carbamoyl ketolide antibacterials ����-������ҩƷ��˾ 2004-11-03 CN disclosed
US-6613747-B2 Erythromycins to treat community-acquired pneumonia and upper and lower respiratory tract, skin and soft tissue, hospital-acquired lung, bone and joint infections; Staphyloccus; Enterococcus; Moraxella; Hemophilus; antibiotic resistance ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-09-02 US disclosed
US-20030013663-A1 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-01-16 US disclosed
US-6472372-B1 6-O-Carbamoyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICALS, INC. 2002-10-29 US disclosed
US-20020115620-A1 6-0-carbamoyl ketolide antibacterials ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013663-A1 6-O-CARBAMOYL KETOLIDE ANTIBACTERIALS Q6ZSR9, KDM4E, HK1 CYP2D6 199/4885MAPT 3982/4885MAPK14 2590/4885
US-20110281832-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 CYP2D6 8/4885MAPT 966/4885MAPK14 4400/4885
US-20150119370-A1 Organic Compounds CYP2C19, CYP2C9, CYP3A43 CYP2D6 17/4885MAPT 497/4885MAPK14 3978/4885
US-20020115620-A1 6-0-carbamoyl ketolide antibacterials Q6ZSR9, HK1, KDM4E CYP2D6 234/4885MAPT 4095/4885MAPK14 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.